Cardiff Oncology, Inc. (CRDF)
| Market Cap | 98.30M |
| Revenue (ttm) | 361,000 |
| Net Income (ttm) | -34.13M |
| Shares Out | 43.31M |
| EPS (ttm) | -0.84 |
| PE Ratio | n/a |
| Forward PE | n/a |
| Dividend | n/a |
| Ex-Dividend Date | n/a |
| Volume | 6,658,653 |
| Open | 2.31 |
| Previous Close | 2.29 |
| Day's Range | 2.14 - 2.57 |
| 52-Week Range | 1.13 - 8.58 |
| Beta | 2.03 |
| Analysts | Buy |
| Price Target | 12.92 (+469.2%) |
| Earnings Date | Aug 4, 2022 |
About CRDF
Cardiff Oncology, Inc., a clinical-stage oncology company, develops medicine treatment for cancer patients in California. Its lead drug candidate is onvansertib, an oral selective Polo-like Kinase 1 Inhibitor for anti-cancer therapeutics; CY140, an inhibitor of PLK1, PLK2, and PLK3 that is in phase 1/2 studies in solid tumors and leukemias; metastatic colorectal cancer that is in clinical trials; and TROV-054 is a Phase 1b/2 for FOLFIRI and bevacizumab. The company's TROV-053 is also in Phase II clinical trial in combination with Zytiga for met... [Read more...]
Financial Performance
In 2021, CRDF's revenue was $359,000, a decrease of -1.91% compared to the previous year's $366,000. Losses were -$28.29 million, 46.5% more than in 2020.
Financial StatementsAnalyst Forecast
According to 12 analysts, the average rating for CRDF stock is "Buy." The 12-month stock price forecast is 12.92, which is an increase of 469.16% from the latest price.
News
Top Penny Stocks To Buy? 4 Biotech Stocks To Watch Now
Biotech penny stocks to watch in June. The post Top Penny Stocks To Buy?
Cardiff Oncology to Present at the H.C. Wainwright Global Investment Conference
SAN DIEGO, May 17, 2022 /PRNewswire/ -- Cardiff Oncology, Inc. (Nasdaq: CRDF), a clinical-stage biotechnology company leveraging PLK1 inhibition to develop novel therapies across a range of cancers, tod...
Cardiff Oncology (CRDF) Reports Q1 Loss, Misses Revenue Estimates
Cardiff Oncology (CRDF) delivered earnings and revenue surprises of -8.70% and 1.33%, respectively, for the quarter ended March 2022. Do the numbers hold clues to what lies ahead for the stock?
Cardiff Oncology Reports First Quarter 2022 Results and Provides Business Updates
Reported new Phase 1b/2 data from lead KRAS-mutated metastatic colorectal cancer (mCRC) clinical program showing objective response rate and median progression-free survival that substantially exceed th...
Cardiff Oncology Announces Departure of Chief Medical Officer
SAN DIEGO , April 12, 2022 /PRNewswire/ -- Cardiff Oncology, Inc. (Nasdaq: CRDF), a clinical-stage biotechnology company leveraging PLK1 inhibition to develop novel therapies across a range of cancers, ...
Cardiff Oncology Announces Updated Clinical and New Biomarker Data from Phase 2 Metastatic Castration-Resistant Prost...
Trial evaluates onvansertib in combination with abiraterone and prednisone in metastatic castration-resistant prostate cancer (mCRPC) patients showing initial abiraterone resistance by rising PSA Diseas...
Cardiff Oncology Announces Data Showing the Combination of PARP Inhibition with Onvansertib Overcomes PARP Inhibitor ...
- Combining onvansertib with the PARP inhibitor (PARPi) olaparib led to statistically significant survival benefits compared to treatment with either agent alone in PARPi-resistant ovarian cancer models...
Cardiff Oncology to Participate in the 2022 Virtual Growth Conference Presented by Maxim Group LLC
SAN DIEGO, March 22, 2022 /PRNewswire/ -- Cardiff Oncology, Inc. (Nasdaq: CRDF), a clinical-stage biotechnology company leveraging PLK1 inhibition to develop novel therapies across a range of cancers, t...
Cardiff Oncology Announces Upcoming Poster Presentations at the AACR Annual Meeting
SAN DIEGO, March 8, 2022 /PRNewswire/ -- Cardiff Oncology, Inc. (Nasdaq: CRDF), a clinical-stage biotechnology company leveraging PLK1 inhibition to develop novel therapies across a range of cancers, to...
Cardiff Oncology to Participate in Cowen's 42nd Annual Healthcare Conference
SAN DIEGO, March 1, 2022 /PRNewswire/ -- Cardiff Oncology, Inc. (Nasdaq: CRDF), a clinical-stage biotechnology company leveraging PLK1 inhibition to develop novel therapies across a range of cancers, to...
Cardiff Oncology (CRDF) Reports Q4 Loss, Tops Revenue Estimates
Cardiff Oncology (CRDF) delivered earnings and revenue surprises of -35.29% and 90%, respectively, for the quarter ended December 2021. Do the numbers hold clues to what lies ahead for the stock?
Cardiff Oncology Reports Fourth Quarter and Full Year 2021 Results and Recent Highlights
SAN DIEGO, Feb. 24, 2022 /PRNewswire/ -- Cardiff Oncology, Inc. (Nasdaq: CRDF), a clinical-stage biotechnology company leveraging PLK1 inhibition to develop novel therapies across a range of cancers, to...
Cardiff Oncology (CRDF) May Report Negative Earnings: Know the Trend Ahead of Q4 Release
Cardiff Oncology (CRDF) doesn't possess the right combination of the two key ingredients for a likely earnings beat in its upcoming report. Get prepared with the key expectations.
Cardiff Oncology Reports Inducement Grant Under Nasdaq Listing Rule 5635(c)(4)
SAN DIEGO, Jan. 31, 2022 /PRNewswire/ -- Cardiff Oncology, Inc. (Nasdaq: CRDF), a clinical-stage oncology company, developing new precision medicine treatment options for cancer patients in indications ...
Cardiff Oncology to Present at the B. Riley Securities 2022 Oncology Conference
SAN DIEGO, Jan. 20, 2022 /PRNewswire/ -- Cardiff Oncology, Inc. (Nasdaq: CRDF), a clinical-stage oncology company, developing new precision medicine treatment options for cancer patients in indications ...
These 2 Nasdaq Stocks Are Poised to Make Big Moves Today
These clinical-stage biotech stocks are headed in opposite directions today.
Cardiff Oncology Slumps On New Data From Lead Program In Metastatic Colorectal Cancer
Cardiff Oncology Inc (NASDAQ: CRDF) posted new data from Phase 1b/2 trial of onvansertib combined with standard-of-care (SOC) FOLFIRI/bevacizumab for second-line KRAS-mutated metastatic colorectal cance...
Cardiff Oncology Announces New Data from Lead Clinical Program in KRAS-mutated Metastatic Colorectal Cancer Showing R...
SAN DIEGO, Jan. 18, 2022 /PRNewswire/ -- Cardiff Oncology, Inc. (Nasdaq: CRDF), a clinical-stage oncology company, developing new precision medicine treatment options for cancer patients in indications ...
Cardiff Oncology Appoints Tod Smeal, Ph.D., as Chief Scientific Officer and Charles Monahan, RPh, as Senior Vice Pres...
SAN DIEGO, Jan. 11, 2022 /PRNewswire/ -- Cardiff Oncology, Inc. (Nasdaq: CRDF), a clinical-stage oncology company, developing new precision medicine treatment options for cancer patients in indications ...
Cardiff Oncology to Host Conference Call and Webcast to Discuss Updated Data from Lead Clinical Program in KRAS-mutat...
SAN DIEGO, Jan. 10, 2022 /PRNewswire/ -- Cardiff Oncology, Inc. (Nasdaq: CRDF), a clinical-stage oncology company, developing new precision medicine treatment options for cancer patients in indications ...
My 3 Top Biopharma Stock Picks for 2022
These three stocks are poised for a major breakout in 2022.
Cardiff Oncology to Present at the H.C. Wainwright BioConnect Virtual Conference
SAN DIEGO, Jan. 4, 2022 /PRNewswire/ -- Cardiff Oncology, Inc. (Nasdaq: CRDF), a clinical-stage oncology company, developing new precision medicine treatment options for cancer patients in indications w...
Cardiff Oncology Announces Upcoming Presentation on Lead KRAS-mutated Metastatic Colorectal Cancer Program at the 202...
SAN DIEGO, Dec. 10, 2021 /PRNewswire/ -- Cardiff Oncology, Inc. (Nasdaq: CRDF), a clinical-stage oncology company, developing new precision medicine treatment options for cancer patients in indications ...
Cardiff Oncology Reports Inducement Grants Under Nasdaq Listing Rule 5635(c)(4)
SAN DIEGO, Dec. 3, 2021 /PRNewswire/ -- Cardiff Oncology, Inc. (Nasdaq: CRDF), a clinical-stage oncology company, developing new precision medicine treatment options for cancer patients in indications w...
1 Cancer Stock on Buyout Watch in 2022
Cardiff Oncology is a prime takeover target heading into 2022.